The AP (6/29, Perrone) reports, "Government health experts said Thursday there are few reasons to continue using metal-on-metal hip implants, amid growing evidence that the devices can break down early and expose patients to dangerous metallic particles." According to the AP, "the Food and Drug Administration asked its 18-member panel to recommend guidelines for monitoring more than a half-million US patients with metal hip replacements." Although the agency "has not raised the possibility of removing the devices from the market, most panelists said there were few, if any, cases where they would recommend implanting the devices."
NuvaRing, a contraceptive approved in 2001, is a flexible plastic-like ring that is inserted into the vagina and which releases a continuous dose of hormones into a women’s system to prevent ovulation. Since NuvaRing’s approval it has become one of the most popular birth control options for women due to the perceived freedom of not having to remember to take a daily pill.
Bloomberg News (6/22, Edney) reports that according to a report from the Food and Drug Administration, "almost 16,800 adverse events associated with metal-on-metal hip implants were reported in the US from 2000-2011." Bloomberg notes that the FDA document found that reports of adverse events with the implants "almost quadrupled to 682 in 2008 from the year earlier, and rose again after a unit of Johnson & Johnson (JNJ) began recalling hip devices in 2010."
Osteoporosis is a disease that is characterized by reduced bone mass and brittle bones. It affects millions of women. To combat bone loss, women often turn to bisphosphonates. Around the age of 30, most women’s bones start to deteriorate faster than they can be rebuilt. The claim is that bisphosphonates combat the deterioration, giving bones a chance to repair themselves.
The New York Times (6/12, O'Connor) "Well" blog reported, "A popular class of drugs used to treat type 2 diabetes may increase the risk of vision problems," according to a study published online June 11 in the Archives of Internal Medicine. After following some 103,000 patients with type 2 diabetes for about 10 years, researchers found that thiazolidinediones "may increase the risk of macular edema, or swelling in the central part of the retina, which can result in blindness in one or both eyes."
Johnson & Johnson has announced that it will stop selling certain vaginal mesh products. In letters dated June 4, 2012, Johnson & Johnson advised judges overseeing transvaginal mesh litigations that Johnson & Johnson had informed the FDA that its Ethicon unit would no longer be selling certain vaginal mesh products. The stopping of sales is a result of numerous complaints of mesh erosion leading to serious pain and injuries. These injuries have resulted in hundreds of lawsuits being filed.